Blue Haven RX

The terms identify Eternum Health LLC, a New Jersey company doing business as Blue Haven RX. The official site publishes customer email and phone contacts; business registration was not independently checked.

Named operator, an attributed physical business address and a working-purpose contact telephone. Distinguish registered or correspondence offices from clinical and dispensing locations; online care does not require a walk-in clinic. Weight: 8%.

The terms name independent Wasef Health and Beluga Health professional entities, while the telehealth consent describes remote clinician review and prescribing only when appropriate. Individual clinician licenses were not matched.

Who the service is for, prescribing or research-use boundaries, and provider information. Weight: 5%.

The home page advertises $149/month semaglutide and $179/month tirzepatide, but its FAQ lists $179 and $259 respectively. The page mentions a three-month introductory offer; it does not clearly reconcile each advertised price with plan length and later charges. Terms say final plan fees appear at checkout, which was not reviewed.

Public prices or a defined quotation process, with recurring or additional charges explained. Weight: 5%.

The terms describe upfront billing, pre-authorization released if no prescription is approved, non-refundable charges after capture, and cancellation at least 48 hours before a renewal date that may occur up to 10 days before the term ends. Portal and email cancellation are described; no transaction or refund request was tested.

Accessible cancellation, refund or ordering terms and a support channel. Weight: 4%.

The reviewed site and privacy notice refer to pharmacy partners but do not identify the specific dispensing business or prescription destination.

Named dispensing partners for care services; analytical documentation or manufacturing information for research businesses. Weight: 10%.

An entity-specific regulatory assessment has not been completed. No clean record or adverse finding is inferred.

Entity/product-specific regulatory notices, enforcement, recalls and their resolution, with dates and jurisdiction. A pharmacy license match alone is not a regulatory-history review. No clean record is inferred from silence. Weight: 10%.

This criterion has not yet been established from the reviewed evidence.

Product- and lot-specific laboratory reports covering molecule identity and purity, with the laboratory, report date and issuer authenticity check. Full credit requires independently established laboratory identity and a traceable verified report. A testing policy or a report for another batch provides limited evidence only; purity does not establish sterility, endotoxin control or treatment safety. Weight: 12%.

This criterion has not yet been established from the reviewed evidence.

An applicable external accreditation, such as LegitScript for healthcare, matched to the exact business or domain in the issuer’s records. A badge alone does not establish current certification. Weight: 3%.

This criterion has not yet been established from the reviewed evidence.

Accessible privacy terms identifying the responsible entities, data uses and applicable health-data notice. A HIPAA claim is not independent verification of compliance; HIPAA is not required of every research business. Weight: 6%.

This criterion has not yet been established from the reviewed evidence.

Specific, dated evidence of relevant security practices or an independently issued audit, with its entity, scope and limits. HTTPS, a marketing seal or a claim of being unhackable is insufficient. Weight: 6%.

This criterion has not yet been established from the reviewed evidence.

Disclosed payment processing, billing authorization and recurring-charge arrangements. No processor brand is preferred and a processor does not certify the provider’s clinical or product quality. Weight: 3%.

This criterion has not yet been established from the reviewed evidence.

Clear product identity and intended use, distinguishing branded medicines, compounded preparations and research materials; presentation and preparation requirements where relevant. A compounded product is not assumed to be an approved generic. Weight: 8%.

This criterion has not yet been established from the reviewed evidence.

Product-specific delivery, temperature and storage instructions, including handling of shipping problems. Refrigeration, freezing or a particular presentation receives no automatic quality bonus. Weight: 5%.

No named dispensing pharmacy or active state-license match was established from the reviewed public pages; generic references to pharmacy partners do not qualify as registry verification.

At least one exactly named dispensing partner matched to an active, unreplaced official state record. This does not verify all partners or all jurisdictions. Weight: 15%.